The patient's own words, at volume

Kicker

Every earlier Scout in this Inquiry read fifteen reviews and a star histogram. This pass read the corpus: 200 of MEDvidi's 221 all-time one-star Trustpilot reviews (90.5%), and 100% of the 63 filed in the trailing twelve months, hand-coded into a failure taxonomy; 146 of the 159 BBB complaint narratives; the star distributions on three independent scoreboards; and Trustpilot's own transparency ledger, which no Scout knew existed. Four findings matter. First, the top driver of a one-star review is not the clinical gate — it is the prescription failing to reach the pharmacy after the visit went fine. Fulfilment failures (eRx never transmitted, provider signature pending, wrong pharmacy, wrong state licence on the script, pharmacy refuses) are 34.1% of all coded one-star reviews against 18.4% for "the provider declined to prescribe" — and in the last twelve months, 33.9% against 25.0%. Second, that operational problem has narrowed rather than shrunk: the no-show problem (28% of 2024's one-stars → 7% in 2026) and the pharmacy-won't-fill problem (14% → 0%) have been largely solved, while the "prescribed but never sent" problem has held share and the clinical-gate problem has nearly tripled its share. Third, the invited-vs-organic question is settled and inverts the usual assumption: Trustpilot's own transparency page reports 429 of 429 reviews in the last twelve months as organic — zero invited, zero verified — and stamps the profile "This company hasn't invited customers recently, so reviews may not be representative." The 4.3 score is not bought with invitations; it is produced by recency weighting, a paid subscription, a 100%-reply-in-24-hours negative-review operation, and a flagging programme that in twelve months challenged 23 reviews, 22 of them one-star and none of them positive. Fourth, the five-star mass is service recovery, not clinical delight: 41% of five-star reviews describe something going wrong, and 43% name the support agent who fixed it. The sibling brand EZCare Clinic — same P.C., same platform, no paid Trustpilot subscription, two reviews in twelve months — has a higher raw mean (4.32 vs 4.19) and a displayed score 0.9 lower (3.4 vs 4.3). That gap is the size of the review operation, measured.

---

Source legend

---

1. What we found

1.1 What the corpus is, and how much of it we actually read

MEDvidi's public patient voice sits on four surfaces. Their sizes and verdicts, all as of 2026-08-19:

What was actually read for this Finding [CODE]:

• 200 one-star Trustpilot reviews in full — every one filed since 2023-11-22, which is 90.5% of the 221 all-time one-star corpus. The 21 not captured are all older than 2023-11-22.
• Coverage of the trailing twelve months is 63 of 63 — complete. Trustpilot's own ?date=last12months&stars=1 filter returns a count of 63; the reviews captured and dated 2025-08-19 or later number exactly 63 [REV-TP]. This is the strongest coverage claim in the Inquiry: for the last year, this is not a sample of the one-star corpus, it is the one-star corpus.
• 200 unfiltered Trustpilot reviews across all stars, 2026-01-16 → 2026-08-18, used for the invited/organic cross-section and the five-star analysis.
• 146 of 159 BBB complaint narratives, 2023-08-31 → 2026-08-03 [REV-BBB-C]. The 13 not read do not exist publicly: BBB states that "some consumers may elect to not publish the details of their complaints."
• 20 Google reviews in full text with star ratings, 2026-08-08 → 2026-08-17 [REV-GOO], plus the full 1,909-review histogram.
• 20 EZCare Clinic reviews in full text plus that brand's full histogram [REV-TPEZ].

Say the bias out loud before using any of it. A review corpus is not a sample. Nobody writes a review because the median thing happened. The people who write are the people who were delighted at the moment of asking and the people who were harmed badly enough to still be angry a week later. 1,258 Trustpilot reviews against a business that a prior Finding estimates serves on the order of 100,000 lifetime patients [PRIOR] is a response rate around 1%. The star distribution is bimodal — 93.6% of Trustpilot ratings are either 1 or 5, with 6.4% in the whole 2–4 middle [REV-TP] — which is the signature of a self-selected corpus, not of a population. Nothing below supports a claim of the form "X% of patients experienced Y."

What a corpus like this is good for is relative structure and change over time: which failure mode dominates the complaints, in what order, and whether that order is moving. Those are questions the selection bias mostly cancels out of, because the same filter applies in every period and to every category. That is how it is used here, and only that.

1.2 The invited-vs-organic question, settled — and it inverts the assumption

Two prior Findings parked this as unanswerable from outside, and both framed the risk in the same direction: that a 4.3 with 17.7% one-star would be "much harsher" if the corpus were organic, i.e. that invitations were propping the score up [PRIOR].

Trustpilot publishes the answer on a page nobody opened. The company-activity page for medvidi.com, data window 2025-09-01 → 2026-08-19 [REV-TPX]:

And the profile carries Trustpilot's own badge: "No recent history of asking for reviews — This company hasn't invited customers recently, so reviews may not be representative" [REV-TP] [REV-TPX]. The business-unit record corroborates it in two independent fields: isCollectingReviews: false and hasRecentlyInvitedUsers: false [REV-TP].

So the 4.3 is not bought with invitations. It is produced by four other things, all of which are visible and all of which are product decisions:

1. A paid subscription. isUsingPaidFeatures: true, hasSubscription: true, profile claimed 2022-09-15, identity + Google Business + bank account all verified [REV-TP] [REV-TPX].
2. Recency weighting. Trustpilot's TrustScore is time-weighted. MEDvidi has 429 fresh reviews; see §1.10 for what happens to a sibling brand that has 2.
3. A negative-review response operation. 100% of negative reviews replied to, mean 0.45 days, 65 negative reviews answered in the window — which is exactly the 63 one-star plus 2 two-star of that window [REV-TP] [REV-TPX]. Every angry review gets a same-day reply.
4. A flagging programme. See §1.7.

One caveat, and it is the honest half of the story. Trustpilot's source accounting says zero invited, but the per-review labels say something narrower and different. In the 200-review cross-section of 2026-01-16 → 2026-08-18, 57 reviews (28.5%) carry verificationLevel: "invited", verificationSource: "invitation", reviewSourceName: "BasicLink" [REV-TP]. A "BasicLink" is a free review link a business places itself — on its own site, or shared by an agent — as opposed to an invitation sent through Trustpilot's own system. Trustpilot's transparency ledger counts only the latter, which is why the two readings differ and why no "Invited" badge renders on the public review cards. Both statements are true and they mean different things: MEDvidi does not run a Trustpilot invitation programme, and MEDvidi does solicit reviews through its own channel.

The composition of that solicited slice is the interesting part [REV-TP] [REASON]:

93% of solicited reviews are five-star; 74% of unsolicited ones are. Strip the solicited slice and the one-star share of this window rises from 14.5% to 19.6% [REASON]. That is a real effect and it is smaller than one might expect, because the unsolicited corpus is also three-quarters five-star. The asymmetry is where the solicitation happens, not how much of it there is — and §1.9 shows where.

1.3 The three scoreboards disagree, and the gap is manufactured

[REV-TP] [REV-GOO] [REV-BBB-R] [WEB]

Three independent surfaces put MEDvidi between 3.86 and 4.3. MEDvidi publishes 4.85 on medvidi.com/reviews/, with the Trustpilot wordmark rendered above it and the caption "Our patients rated their providers" — and feeds search engines a JSON-LD aggregateRating of 4.4 over 1,197 reviews, a count that no longer matches Trustpilot's 1,258 [WEB] [REV-TP]. A prior Finding established the 4.85 pairing [PRIOR]; this pass confirms it is still live on 2026-08-19 and adds the second and third outside readings, which both land a full point below it.

The 1★ gap between Trustpilot (17.6%) and Google (24.0%) is the sharper number. Same company, same patients, same period — 6.4 points of difference. Google is the surface where MEDvidi has no subscription, no review link, and no flagging channel. The freshest slice is worse still: of the 20 most recent Google reviews (2026-08-08 → 2026-08-17), nine are one-star and one is two-star — 50% negative in a ten-day window [REV-GOO], against 19% one-star on Trustpilot for the whole of August 2026 [REV-TPX]. Twenty reviews is not a sample either; it is a warning that the gap between the two surfaces may be widening, and it is checkable monthly.

1.4 The failure taxonomy: 200 one-star reviews, hand-coded

Every captured one-star review was read in full and assigned one primary root-cause code — the thing that actually broke, not the thing the reviewer asked for. Almost every one-star review asks for a refund; refund-seeking is coded BILLING only when an unexpected or disputed charge was the grievance, not when a refund was the remedy sought for some other failure. Coding rules and judgement calls are in §3.

Thirteen reviews were classified as not about MEDvidi — they describe compounded GLP-1 in vials shipped monthly to the door, auto-renewing subscriptions, melted medication, and price ladders in the $179–$400 range, which is the model of a different company, MEDVi, whose name collides with MEDvidi's; two more are ambiguous. Those 15 are excluded from the base below and handled in §1.8.

All coded one-star reviews, MEDvidi-attributable base n=185 [CODE]:

Grouped into the six things a product organisation could own:

1.5 The commissioning question, answered

"The difference between 'no prescription' and 'pharmacy refused' as the top driver is the difference between a clinical-gate problem and an operations problem."

It is an operations problem, by 1.9 to 1 over the whole corpus and by 1.4 to 1 in the last twelve months — and the operations problem has narrowed to a single step.

Trailing twelve months, MEDvidi-attributable one-star reviews, n=56 [CODE]:

Read that table twice. PHARMACY — "the pharmacy refused to fill it" — is 1.8% of the last year's one-star reviews, down from 14% in 2024. That failure mode is essentially gone. So is NO_SERVICE, at 7.1% against 28% in 2024. What has not gone away is the step between the provider saying yes and the pharmacy receiving the script. That is one queue, and it is the single largest source of one-star reviews in the business.

The patients describe it identically across three years, and the description is always the same three-part shape — the visit was fine, the provider agreed, and then nothing happened:

"Appointment went great, but then it came time for my prescription to be called in. Now on day 13 and still don't have it called in to the pharmacy. Have given them 3 different pharmacies to use and still nothing! Keep getting the run around with customer service. Paid $195 for nothing!" — Google, 2026-08-16 [REV-GOO]

"Absolutely unacceptable experience with MedVidi. They took my money, my doctor prescribed my ADHD medication, and DAYS later the prescription still hasn't even been sent to the pharmacy. Today is Monday evening — I've been contacting them since THURSDAY." — Trustpilot, 2026-05-12 [REV-TP]

"I have never waited so long to have a prescription sent to my pharmacy. It's 2025 and waiting days for an electronic prescription to be sent to a pharmacy is wild. Every time I call they say 'wait of' then '24hrs' then '48 hrs' and now I'm being told it's '72 hrs.'" — Trustpilot, 2025-12-10 [REV-TP]

"I had my appointment. The Dr was great. However, my prescription was never sent to the pharmacy… it says 'prescription preparation' for the last 2 days. How long does it take to prepare a prescription?" — Trustpilot, 2024-02-25 [REV-TP]

Three mechanical details recur inside that queue and are worth naming because they are each a distinct fix:

1. A provider signature step that is asynchronous and unmonitored. "Waiting for the provider's signature" / "awaiting the provider's response" appears verbatim across 2023, 2024, 2025 and 2026 [REV-TP]. One reviewer waited two days for a signature after already being two weeks without medication in a national shortage (Trustpilot, 2026-01-10).
2. Pharmacy re-routing is manual and patient-driven. When a pharmacy is out of stock, the patient is told to find another one, and then the resend is slow enough that the second pharmacy sells out too. "This is now the third pharmacy I have had to provide solely because Medvidi failed to act with urgency" — Trustpilot, 2026-01-10 [REV-TP]. Another: "I changed my pharmacy in the portal, and called just to be sure… They sent it at exactly 8pm. When the pharmacy was closed" — Trustpilot, 2025-11-05 [REV-TP].
3. Fax, in 2026. One reviewer discovered the fax number printed on MEDvidi's own records-release form was invalid, and separately that Walgreens' fax number was recorded wrong on their prescription: "It shouldn't be on me to do their work for them acquiring fax numbers for a pharmacy" — Trustpilot, 2025-09-28, 2025-09-27 [REV-TP].

The clinical gate is the second driver and it is real, but it is a different kind of problem. It is almost always the same complaint: the patient learned the answer was no only after paying.

"Waste of time and of $200.00. What a scam, and rip off. You couldve told me before my appointment that i didnt qualify." — Trustpilot, 2025-10-15 [REV-TP]

"This company is a scam. The provider outright stated that the questionnaire did not provide enough data for her to make a diagnosis. So I paid $200 to be referred to an alternate company." — Google, 2026-08-12 [REV-GOO]

"The website advertises that doctors can prescribe anti-anxiety medications via a telehealth appointment but upon paying an absorbitant fee the doctor… said that such medications can not be prescribed without an in person diagnosis." — BBB complaint, 2026-04-15 [REV-BBB-C]

That is not a clinical problem. Declining to prescribe a Schedule II stimulant to someone who does not meet criteria is the system working. It is a sequencing problem: MEDvidi takes the money before the eligibility answer exists, so every legitimate clinical "no" converts into a refund fight, a one-star review, and a BBB complaint. §6 argues what to do about it.

1.6 The time series, 2023 → 2026

Counts are of MEDvidi-attributable one-star Trustpilot reviews, hand-coded, by calendar year of publication [CODE]. 2023 begins 2023-11-22 (12 reviews only — treat as directional); 2026 runs to 2026-08-18.

Four things happened, and they are not the same thing:

1. The company fixed showing up. In 2024, 28% of one-star reviews were "the provider never joined the call" or "you cancelled on me three times." By 2026 that is 7%. The 2024 corpus is full of patients waiting one, two, three hours in an empty video room; the 2026 corpus barely mentions it.
2. The company fixed the pharmacy network. 14% of 2024's one-star reviews were a pharmacy refusing to fill — because the prescriber was not licensed in the patient's state, or the pharmacy did not accept MEDvidi at all. In 2026 that is zero of 28. Reviewers in 2024 wrote "very few pharmacies work with medvidi" and "Walmart wouldn't fill a controlled substance from a televisit"; in 2026 a five-star reviewer writes the mirror image — "Finally someone who will wrestle Walgreens into filling" (Trustpilot, 2026-07-23) [REV-TP].
3. The company did not fix transmission. RX_NOT_DELIVERED has held or grown its share every year and is now the largest category. It is what is left after the two easier problems went away.
4. The clinical gate is the fastest-growing complaint — 13% → 17% → 36% of the year's one-star reviews. That share growth is partly arithmetic (the denominator shrank as other categories were fixed) and partly real: the 2026 corpus contains more patients who were assessed, refused, and not refunded than any prior year. It is also the category most likely to grow further as the DEA telemedicine flexibilities approach expiry [PRIOR].

Absolute volume is falling too. Trustpilot's own monthly ledger, trailing 12 months [REV-TPX]:

And the two-period split that is robust to monthly noise [REV-TP] [REASON]:

• Trailing 12 months: 63 one-star of 453 reviews = 13.9%
• Everything before that: 158 one-star of 805 = 19.6%
• A 29% relative reduction in the one-star rate.

The other half of that table is more interesting than the ratio. Review inflow fell 59%, from 168 in Sep–Nov 2025 to 69 in Jun–Aug 2026 [REV-TPX]. Either patient volume is falling, or the review-solicitation channel was throttled, or both. A prior Finding independently estimates declining site traffic [PRIOR]; this is a second, differently-sourced signal pointing the same way, and it is the single number in this Finding a candidate should be most careful about, because it has two very different explanations and this corpus cannot separate them (see §4).

The BBB series moves the same direction, on an entirely separate corpus. Complaint narratives by calendar year, counted from the 146 read [REV-BBB-C] [REASON]:

Two independent complaint channels, both falling, both by roughly a third. That is the most defensible directional statement in this Finding.

1.7 What the flagging programme does to that time series

Trustpilot publishes the business's own moderation record. MEDvidi, trailing 12 months [REV-TPX]:

So in twelve months MEDvidi challenged 23 reviews, every one of them negative, and Trustpilot found 17 of those challenges to be without merit. Five reviews were removed — none of them because the complaint was substantiated, all five because the reviewer never answered Trustpilot's request for documentation.

Patients noticed, and wrote it down, repeatedly, over three years:

"After posting this review, MedVidi responded to this post and also reported it for 'illegal or harmful content'. My guess, is in an attempt to have bad reviews scrubbed… Medvidi is bending over backwards now trying to get this review removed. They've spent more effort on this, than getting my appointment taken care of." — Trustpilot, 2024-11-20 [REV-TP]

"As of today, I have been notified that MedVIDI has attempted to flag my review as 'defamatory.' After less than a half hour, it seems TrustPilot saw through MedVIDI's ridiculous attempt to discredit my real account." — Trustpilot, 2024-08-23 (December 2024 update) [REV-TP]

"They once again tried to have my review removed. Still don't have my medical records." — Trustpilot, 2023-12-19 [REV-TP]

"They contacted me to 'make it right' so that I would remove this review — they have not 'made it right' yet." — Trustpilot, 2023-11-28 [REV-TP]

Two consequences. First, the downward trend in one-star volume in §1.6 is biased downward by roughly 5 reviews a year — about 8% of the annual one-star flow — and the bias is entirely one-directional, because zero positive reviews were ever flagged. The trend survives that correction (a 29% relative drop does not become nothing when you add back 8%), but the number should always be quoted with the correction attached. Second, and more usefully for a candidate: this is a measurable, dated, adversarial-moderation record that a CEO cannot dispute, because Trustpilot published it, and it costs the company reputation every time a reviewer edits their review to say the removal was attempted.

A third thing recurs and is worse than flagging, because it is upstream: reviewers report being asked for a positive review as part of, or in place of, the fix.

"It seems all anyone cares about is that I leave a good review and they will tell me anything I want to hear in order to get a good review." — Trustpilot, 2025-02-11 [REV-TP]

"I was told maybe they could get my situation correct if I wrote a helpful review. In wishful thinking I did such." — Trustpilot, 2025-09-17 [REV-TP]

"Fiya was really helpful in dealing with my problem and got on it right away I did this to quick she just wanted a review she never handled my problem" — Trustpilot, one-star, 2025-10-14 [REV-TP]

That last one is a five-star-shaped review filed at one star, and it is the tell for §1.9.

1.8 BBB: 146 complaint narratives, and the MEDVi contamination, quantified

BBB's published structure for "Medvidi Inc", read 2026-08-19 [REV-BBB-C] [REV-BBB-P]:

• 159 complaints in three years, 58 closed in the last twelve months. A+ rating, BBB Accredited since 2025-03-07, business started 2020-04-08, incorporated 2021-09-06.
• Alternate business names: EZCare Clinic and Mango Clinic. Two locations: 4010 Moorpark Ave #114, San Jose CA and EZCare Clinic, San Francisco CA 94102.
• Business management listed as Ms. Laura Purdy, CEO and Mr. Vasili Razhnou, Secretary — a contradiction with the company's own site that a prior verification pass has already caught and adjudicated [PRIOR]; not re-litigated here.
• Complaint types: Service or Repair 70 · Product 56 · Customer Service 10 · Sales & Advertising 9 · Billing 8 · Order 5 · Delivery 1.
• A brand-confusion alert MEDvidi placed on its own BBB profile: "MEDvidi Inc is a separate and unaffiliated company from any other similar-sounding entities, including MEDVI."

The contamination question, settled with a number. Two prior Findings flagged that BBB complaints about a different company, MEDVi (a compounded-GLP-1-by-mail subscription business), land on MEDvidi's profile, and called it a real but unquantified reputational tax [PRIOR]. It is now quantified.

Of the 146 narratives read, 12 describe a business MEDvidi does not operate — monthly subscription billing for medication shipped to the door, tirzepatide and semaglutide vials, price ladders at $179 → $350 and $399.01, and in two cases BBB's own resolution text records that MEDvidi replied that the charges "didn't match Medvidi's actual services" and the complainant accepted it. In one, the consumer states outright that they "realized they had filed against the wrong company" [REV-BBB-C]. MEDvidi is a pay-per-visit prescribing clinic that ships nothing; "Delivery Issues: 1" on a business with no deliveries is the same artefact showing up in BBB's own category counts.

The distribution of those 12 is the useful part [REASON]:

The contamination is not historical background noise — it started in late December 2025 and now runs at roughly a quarter of MEDvidi's incoming BBB complaints. Applying that rate to the published count: of the 58 complaints closed in the last twelve months, roughly 13 are somebody else's, and MEDvidi's own trailing-twelve-month figure is approximately 45 [REASON]. The assumptions are stated: that the 53 narratives read are representative of the 58 closed (they are nearly all of them), and that a complaint describing shipped compounded GLP-1 with auto-renewal is not MEDvidi's. A candidate should quote 45, show this arithmetic, and say the word "approximately."

Note also what this resolves: the contradiction two Findings left open between "159 complaints" and "185 complaints" [PRIOR] is a window artefact, and both are inflated by the same third-party noise. The number worth defending is neither 159 nor 185: it is ~45 MEDvidi complaints in the trailing twelve months, falling.

The complaint corpus itself tells the same story as the reviews, with two additions the review corpus under-represents:

• Records access. BBB carries a run of complaints about the $6.50 records fee being taken and the records never arriving, HIPAA release forms bouncing on an invalid fax number, and one refusal to release records on the grounds that a digital signature did not match a fifteen-year-old driving-licence signature [REV-BBB-C] [REV-TP]. HIPAA's right-of-access rule has a 30-day clock and a federal enforcement channel; several complainants say they filed there. This is a compliance exposure sitting inside a support workflow.
• A complaint from a practitioner. One 2024-09-02 BBB complaint is filed by someone identifying as a practitioner, alleging the company "fraudulently charge and destroy medical records" and that practitioners left over the medical director's conduct [REV-BBB-C]. Unverified, and singular. Parked in §4 — but it is the only public clinician-side complaint this Inquiry has found through any channel, and its existence is worth knowing.

1.9 The five-star mass is service recovery, not clinical delight

This is the finding with the largest product consequence and it took reading the positives to see.

Of the 159 five-star reviews in the 2026-01-16 → 2026-08-18 window [CODE] [REV-TP]:

Compare the one-star median: 546 characters, four times longer [CODE]. Angry patients write essays; happy ones write a line.

Read the five-star reviews and the shape is unmistakable. They are overwhelmingly not "the treatment worked." They are "something broke and a named human fixed it":

"Zayn is a gem! I've struggled with dropped or failed connections for these virtual visits in the past, and being told to pay a $100 rescheduling fee when I was there and waiting online is absurd." — Trustpilot five-star, 2026-08-16 [REV-TP]

"I had to call in regarding a tech problem connecting to the video chat, and as a result, the doctor terminated the appointment while I was on the phone with [agent]… she managed to reschedule my appointment at no additional charge. She was great." — Trustpilot five-star, 2026-08-11 [REV-TP]

"Their IVR/voicebot system has unfortunately been unreliable in my experience; it sometimes becomes muffled, disconnects, or hangs up. This happened while I was trying to reschedule… Thankfully, my second call went through" — Trustpilot five-star, 2026-08-18 [REV-TP]

"Everyone that I dealt with was not great and made me wait hours just to tell me they are going to charge me $100 for something that shouldn't be my fault. [Agent] was the last person I talked to and she was great." — Trustpilot five-star, 2026-07-30 [REV-TP]

Google looks the same: "My issue was solved immediately!"; "[Agent] was very quick to escalate my concern and got it taken care of"; "the team helped me resolve it immediately" — all five-star, all about resolution of a failure [REV-GOO].

Trustpilot's own AI summary of the corpus reaches the same place independently: "the medical staff and support team are incredibly compassionate, helpful, and remarkably quick to resolve appointment or prescription issues" [REV-TP] — note that the top-line praise in a review corpus of a medical practice is about issue resolution.

Three consequences, and they compound.

1. The score is measuring the support organisation, not the clinical product. Any dashboard that treats the Trustpilot or Google rating as a proxy for care quality is mis-instrumented.
2. The solicitation fires at the moment of recovery. 93% of solicited reviews are five-star (§1.2), and the recovery moment is when an agent has just delighted someone. That is a defensible practice — and it is also the mechanism that converts an operational failure into a five-star review, which means the review score partially rewards the failure rate. A company that eliminated the failures would lose the recovery moments and, mechanically, some of its five-star flow.
3. It is a fragile asset. The support layer is doing the reputational work of the product. A prior Finding notes MEDvidi has shipped an agentic AI receptionist across SMS, portal chat, web chat and voice [PRIOR]. The reviews already contain the collision: patients five-star the humans and complain about the bot — "Their IVR/voicebot system is bad" (five-star, 2026-08-18); "the automated system hangs up on you" (one-star, 2026-04-12); "their phone number is not monitored by a human and will just put you on hold and hang up on you after 5 min" (one-star, 2025-10-30) [REV-TP]. If the AI receptionist deflects the recovery conversations, it deflects the five-star reviews with them. That is a testable, dated hypothesis and it is in §6.

1.10 The sibling brand: same taxonomy, different score

Nobody had looked at EZCare Clinic. It is a MEDvidi DBA on the same BBB profile [REV-BBB-P], running on the same clinical operations platform [PRIOR], with its own Trustpilot presence [REV-TPEZ]:

[REV-TP] [REV-TPEZ]

EZCare's raw distribution is slightly better than MEDvidi's, and its displayed score is a full point worse. 4.32 versus 4.19 on the arithmetic; 3.4 versus 4.3 on the scoreboard. The entire gap is produced by Trustpilot's recency weighting operating on a corpus that stopped growing — two reviews in twelve months against 429.

That is the free experiment §2.1 of the gaps critique asked for, and it separates brand from platform cleanly:

• Score is a review-operations artefact. Same P.C., same platform, same clinicians, near-identical patient sentiment, one full star of difference in what the public sees. MEDvidi's 4.3 is bought with review volume, recency, a subscription and a same-day reply desk — not with better care.
• The failure taxonomy is platform-level, not brand-level. EZCare's one-star reviews are the same eleven categories in roughly the same order [REV-TPEZ]: "prescription was never sent to the pharmacy by the provider so I waited" (2025-05-20); "No provider continuity or prescribing consistancy… I've been scheduled with 3 different providers over the last three months" (2025-04-03); "Walgreens would not fill it because the doctor does not have a FL address near my zip code" (2024-07-18); "Their website specifically says they prescribe controlled substances… After paying quite a bit of money to talk to the doctor, I was told that the information given on the site wasn't true" (2024-06-19); "the call center representatives repeatedly read from the same script, stating they are waiting for the doctor to sign off. This is the third time I have had to wait weeks for my prescription" (2024-05-24).
• Patients already know the brands are one company. "Medvidi and EZcare are symbiotic companies. The review will be the same since both are affiliated with each other" — EZCare Trustpilot, 2024-10-14, a review whose text is a verbatim cross-post of a MEDvidi review from the same day [REV-TPEZ] [REV-TP]. Another: "Shame on MEDvidi mango clinic and EZ Care!!!!" — MEDvidi Trustpilot, 2024-03-19 [REV-TP]. And: "I started when they were still 'EZcare' before they merged with Medvidi. As soon as the merge happened, I believe it was in October, this place has been on a steady decline" — MEDvidi Trustpilot, 2023-12-07 [REV-TP].

Mango Clinic is gone as a separate Trustpilot identity. trustpilot.com/review/mangoclinic.com now resolves to the MEDvidi profile, and Trustpilot's merge ledger records the event precisely: 2026-01-08, one profile merged into MEDvidi, reason REBRANDING, mangoclinic.com, 1 review carried over, merged initial TrustScore 3.2, MEDvidi's TrustScore unchanged at 4.3 [REV-TPX]. That single record does two useful things: it dates a brand consolidation nobody had dated, and it proves the 1,258-review corpus is not contaminated by sibling-brand history — only one review came across, and EZCare's 411 remain in a separate, live, unmerged profile.

1.11 Reddit: four ways in, all closed

The gaps critique asked specifically for Reddit, on the correct reasoning that r/ADHD, r/adhdwomen and r/PMHNP are where patients compare clinics on the axis MEDvidi sells. Four independent access routes were attempted on 2026-08-19 and all four refused [NULL]:

Reddit is not merely "hard" from this environment; it is closed. This is stated plainly rather than papered over, because a candidate who claims to have read Reddit threads and then meets a CEO who has actually read them is in the worst possible position. The honest sentence is: "I could not get Reddit. Everything I'm telling you about patient sentiment comes from 1,258 Trustpilot reviews, 1,909 Google reviews and 159 BBB complaints, all of which I did read." That is a stronger position than a vague gesture at "the subreddits."

What partially substitutes: the corpus already contains patients doing comparison shopping in public, naming the alternatives they left for. "I urge potential patients to explore alternatives — services like Circle Medical or ADHD Online may offer the respectful, evidence-based care this lacked" — Trustpilot, 2026-02-06 [REV-TP]. "there are other telehealth companies that can prescribe controlled medication" — Trustpilot, 2024-05-01 [REV-TP]. Circle Medical is the competitor A6 independently nominated as MEDvidi's real rival [PRIOR]; here is a patient naming it unprompted at the moment of churn.

1.12 Two operational details the corpus reveals that no other source did

1. The support desk is outsourced or offshore, and patients say so constantly. "the 'help' line is just an answering service in another country and they can't do anything" (2024-12-19); "they go through a 3rd party company who handles all of this, so there is no direct way to communicate with them" (2025-09-28); "There is no US-based customer support available" (2025-07-15); "the customer service that has little English comprehension" (2023-11-30) [REV-TP]. A prior Finding rests a load-bearing claim about support language barriers on a single Glassdoor line [PRIOR]; this corpus corroborates it from the patient side, dozens of times, across three years. The mechanism patients describe is consistent and specific: the agent can log a request but cannot action it, so every request becomes "I've escalated it to the team."
2. Patients cannot message their own provider. "You cannot directly message your own provider" (Google, 2026-08-16); "They don't let you contact your doctor directly" (2023-11-30); "the only way to speak to a 'provider' directly is to pay 200 dollars again" (Google, 2026-08-16); "their only response will ever be, pay another 170 dollars and schedule another 15 min appt" (2025-12-19) [REV-TP] [REV-GOO]. One reviewer reports being told this was a DEA requirement and rebutting it with the DEA's own guidance (2023-11-30) [REV-TP]. Whether that policy is clinical, economic or regulatory, it is the structural cause of the largest complaint category: when the script does not arrive, the patient has no channel to the only person who can fix it.

---

2. Capability / object table

---

3. Reconciliation notes

R1 — "Invited vs organic": two true readings, and both must be quoted together. Trustpilot's transparency ledger says 0 invited of 429 in twelve months [REV-TPX]; the per-review labels say 28.5% of the 2026 cross-section are verificationLevel: invited [REV-TP]. These are not in conflict: the ledger counts invitations sent through Trustpilot (automatic + manual, both zero), while the per-review label marks a reviewer who arrived through a company-placed review link ("BasicLink"), which Trustpilot's source accounting classifies as organic. Resolved in favour of stating both: MEDvidi runs no Trustpilot invitation programme and does solicit reviews through its own link, and that solicited slice is 93% five-star. Anyone who quotes only the first half will be wrong about how the five-star mass forms; anyone who quotes only the second will be contradicted by Trustpilot's own page.

R2 — Trustpilot's numberOfReviewsLast12Months moves and disagrees with the filters. Three numbers exist for "reviews in the last twelve months": 421 (business-unit field, pulled 08:24), 429 (same field, pulled 09:00, and the transparency ledger's calendar-month sum for 2025-09 → 2026-08), and 453 (the ?date=last12months filter's rolling count from 2025-08-19) [REV-TP] [REV-TPX]. The gap is a window definition, not an error: 453 − 429 = 24 reviews from 19–31 August 2025. Rule applied throughout: use 429 and the monthly ledger for anything described as "the last twelve months" as Trustpilot accounts for it; use 453 only for the rolling-window one-star share, where the numerator (63) came from the same rolling filter.

R3 — Coding rules, and the two calls a reasonable person could make differently. Each review carries exactly one primary code, assigned to the root cause, not the remedy sought. Two rules do real work and should be disclosed: (a) Refund-seeking is not BILLING. Almost every one-star review demands a refund. BILLING is assigned only when an unexpected, duplicated or disputed charge was the grievance itself (no-show fees, price changes, double charges). Coding it on mention would have made BILLING 38% of the corpus and would have been meaningless. This is the single largest judgement in the coding and it moves BILLING from ~38% to 4.9%. (b) The line between RX_NOT_DELIVERED and PHARMACY. If the script left MEDvidi and the pharmacy would not or could not fill it (licensure, telehealth policy, stock, drug discontinued), it is PHARMACY. If the script never left, arrived days late, was unsigned, was written wrong, or went to the wrong pharmacy, it is RX_NOT_DELIVERED. Reviews describing both were coded to the first failure in time. The headline finding does not depend on this line: the two together are 34.1% either way, against 18.4% for the clinical gate. A third disclosure: the eleven-category taxonomy is wider than the eight the gaps critique specified, because the corpus contained two recurring failures the critique's list had no home for — records access and continuity break — and folding them into "support" or "billing" would have hidden them.

R4 — The 2026 column is thin. 2026 has 28 MEDvidi-attributable one-star reviews. Every percentage in that column has a margin of roughly ±9 points at one standard error. The directions — pharmacy to zero, no-show collapsing, clinical gate rising — are consistent with the 2025 column and with the twelve-month cut (n=56), which is why they are stated; individual 2026 percentages are not load-bearing and should be quoted as "roughly."

R5 — The falling one-star trend is real but flattered. Five one-star reviews were removed in twelve months through the flagging channel, all for consumer non-response, and zero positive reviews were ever flagged [REV-TPX]. Add them back and the trailing-twelve-month one-star count is 68 rather than 63, and the share 15.0% rather than 13.9% — still well below the 19.6% prior-period rate [REASON]. The trend survives; the number should carry the asterisk.

R6 — The BBB "159 vs 185" contradiction is resolved and superseded. A prior verification pass flagged that Findings printed both 159 (live, August 2026) and 185 (Wayback, March 2026) for the same metric [PRIOR]. Both are rolling three-year windows read at different dates, so both can be right; the live figure on 2026-08-19 is 159 [REV-BBB-C]. More importantly, neither is MEDvidi's complaint rate, because ~23% of the recent flow belongs to MEDVi (§1.8). The number to use is ~45 in the trailing twelve months, with the arithmetic shown.

R7 — Against [PRIOR]: "the company exited therapy" and the sibling-brand question. A prior pass flagged a contradiction between "MEDvidi exited therapy" and EZCare selling therapy [PRIOR]. This pass does not resolve it, but it adds a fact that bears on it: EZCare's Trustpilot profile has received two reviews in twelve months [REV-TPEZ]. Whatever EZCare's website still offers, the brand is not acquiring meaningfully. Any argument that treats EZCare as a live second front should account for that.

R8 — Against [PRIOR]: the "4.85/5" is worse than one Finding stated. A prior Finding established that MEDvidi displays 4.85 under a Trustpilot wordmark while Trustpilot reports 4.3 [PRIOR]. Two further outside readings now exist — Google at 3.92 and BBB at 3.86 [REV-GOO] [REV-BBB-R] — so the claimed figure is roughly a full point above every independent measurement, not 0.55 above one of them.

---

4. Open Questions / Parked

1. Is the 59% collapse in review inflow a demand signal or a solicitation signal? Reviews fell from 168 (Sep–Nov 2025) to 69 (Jun–Aug 2026) [REV-TPX]. Two very different explanations — fewer patients, or a throttled review link — and this corpus cannot separate them. Settled by: internal visit volume for the same months, or the answer to "when did we change how we ask for reviews." A candidate should ask this and should not guess at it.
2. What is the actual eRx-to-pharmacy latency distribution? Patients describe 2, 6, 9, 13, 24 days. The complaint corpus is the tail; the median is invisible from outside. Settled by: the internal timestamp between "provider signed" and "transmission accepted by pharmacy," which certainly exists in the platform.
3. What fraction of paid initial visits end in no prescription? The clinical gate is 25% of the last year's one-star reviews and rising, but the corpus cannot say whether that is 2% or 30% of visits. Settled by: internal only. This is question 5 on the gaps critique's list of what the CEO will ask [PRIOR], and this Finding sharpens why it matters rather than answering it.
4. Does the AI receptionist deflect the recovery conversations that generate five-star reviews? §1.9 makes this testable: correlate the deflection rate of the agentic receptionist by month against five-star review volume and against the share of five-star reviews naming a human agent. The public data supports the hypothesis and cannot confirm it. Settled by: internal, in an afternoon.
5. Who is the outsourced support provider, and what is the agent's actual permission set? Patients consistently describe agents who can log but not act. Settled by: internal — but the question itself is a good one to ask in the room.
6. The practitioner-filed BBB complaint (2024-09-02). Alleges destroyed medical records and practitioner attrition driven by the medical director [REV-BBB-C]. Single-sourced, unverified, consumer-written. Parked and flagged, not used.
7. Reddit, and the clinician communities. Closed from this environment (§1.11). r/PMHNP and allnurses would also close the clinician-voice gap the critique names [PRIOR]. Settled by: a logged-in browser session on a residential connection, or a Reddit API key.
8. The 21 one-star reviews older than 2023-11-22. Trustpilot's deep pagination redirects to a login wall after roughly ten consecutive requests. They would extend the time series back to the 2022 profile claim. Low value: the 2023 column is already thin and the business changed shape at the EZCare merge.
9. Whether the "MEDVi" complaints are truly MEDVi's and not Mango Clinic's. Mango is a MEDvidi DBA that sells weight loss [REV-BBB-P], so shipped-medication complaints could in principle be the house's own. Judged against MEDVi because MEDvidi's model is pay-per-visit prescribing with nothing shipped [PRIOR], and because the specific price points ($399.01, $179→$350) match MEDVi's published ladder [PRIOR]. If a CEO says "some of those are Mango's," that is a fair challenge and the honest answer is that the 12 break down as 10 near-certain and 2 arguable.
10. BBB customer-review star distribution. BBB publishes 459 reviews at a 3.86 mean but the histogram did not render [REV-BBB-R]. Would let the third scoreboard be compared on 1★ share rather than only on mean.

---

5. What this does NOT cover

• Any population claim. This is a self-selected corpus with roughly a 1% response rate against the patient base a prior Finding estimates [PRIOR]. Nothing here says what fraction of patients experience anything.
• Clinician voice. Glassdoor, Indeed, r/PMHNP and allnurses were not attempted in this pass; one practitioner-filed BBB complaint is the entire clinician-side evidence here, and it is parked. The gaps critique's §2.2 remains open [PRIOR].
• Reddit. Documented failure, four routes (§1.11).
• Non-English reviews. Trustpilot's filtered corpus is ~1,185 English reviews; the four Spanish reviews Trustindex reports were not read [REV-TP] [REV-GOO].
• Google reviews beyond 20 full texts. The Trustindex aggregator paginates over AJAX and resisted deep extraction; the 1,909-review histogram is complete but only the 20 most recent narratives were read [REV-GOO].
• App-store reviews. MEDvidi has no native mobile app [PRIOR]; there is nothing to read.
• Whether any specific allegation in any review is true. Every quotation here is a consumer's unverified account. Individual clinicians named by reviewers have been redacted throughout, deliberately: allegations about named private individuals are not evidence and are not this Inquiry's business.
• Comparative review corpora for competitors. Circle Medical, Klarity and Done were not pulled. Without them, "17.6% one-star" has no benchmark and should never be quoted as good or bad in isolation — only its own trend is defensible.
• The economics of any of this. Refund rates, chargeback rates and the cost of the support organisation are not derivable from reviews and are not attempted.

---

6. What this means for a VP of Product

The argument in one line: MEDvidi has already fixed the two hard-looking problems and left the easy-looking one alone, and the easy-looking one is now both the largest source of patient anger and the thing whose fix would remove the very failures its five-star reviews are made of.

1. The first build is the transmission queue, and the corpus tells you its exact shape. Between 2024 and 2026 this organisation solved provider no-shows (28% → 7% of one-star reviews) and solved the pharmacy network (14% → 0%). Both were genuinely hard: one is clinical-supply scheduling, the other is a licensure-and-acceptance problem across 35 states. Meanwhile the step between "provider clicked prescribe" and "pharmacy received it" has held or grown its share every single year and is now 34% of all one-star reviews and 34% of the last twelve months'. It is the only category that has never improved. And it is not one problem, it is three, each with a different owner: an asynchronous provider-signature step with no SLA and no visible queue, a manual patient-driven pharmacy re-route that loses to stock churn, and a transmission layer still partly running on fax. None of those is a model problem. All three are a workflow with no clock on it. The instrumentation to prove it takes a day — the platform already has the timestamps — and the fix is a queue with an ageing view, an escalation rule, and a status the patient can see. A candidate who walks in and says "your biggest patient-facing failure is a signature queue, here is the evidence, and I would put a clock on it in week one" is having a different conversation from one who says "I'd improve the patient experience."

2. Move the eligibility answer in front of the paywall — the review corpus is now the second independent argument for it. Two prior Findings recommended a pre-payment eligibility gate on funnel logic [PRIOR]. This corpus supplies the demand-side proof: the clinical gate is the fastest-growing complaint category (13% → 36% of one-star reviews) and the complaint is never "the doctor said no" — it is always "you could have told me before you took $195." That includes patients in states MEDvidi does not serve, patients matched to providers not licensed where they are, patients whose sought drug class the practice will not prescribe, and patients whose questionnaire never reached the provider. Every one of those is knowable before payment. This is not a growth idea; it is the conversion of a legitimate clinical "no" from a refund fight into a referral, and — with the DEA telemedicine flexibilities expiring 2026-12-31 [PRIOR] — the same screen is the surface where a lot more people are about to be told no. Building the gate is building the December contingency. That is the sequencing argument the gaps critique said nobody had made.

3. Know what your NPS is actually measuring before you optimise it. 43% of five-star reviews name a support agent and 41% describe something going wrong. The score is a service-recovery metric wearing a care-quality costume. Two consequences a VP of Product must hold at once. First, any goal of the form "raise our rating" currently routes to "run a better recovery desk," which is the opposite of removing the failures. Second, and sharper: the agentic AI receptionist is a direct threat to the five-star flow. If it deflects the calls where a named human currently rescues a patient and earns a five-star review, the rating falls even as the underlying experience improves — and the reviews already show the collision, with patients five-starring humans in the same breath as they complain about the voicebot. The eval that matters for that agent is therefore not containment rate. It is recovery rate: of conversations the agent handled end-to-end, what share ended with the patient's problem actually resolved, measured against the human baseline. That is a concrete, defensible answer to "what does AI evals mean here," and it comes straight out of this corpus.

4. The reputation operation is a liability disguised as an asset, and the sibling brand proves it. MEDvidi's 4.3 costs a Trustpilot subscription, a 100%-reply-within-24-hours desk, and a flagging programme that in twelve months challenged 23 reviews — 22 of them one-star, none of them positive — of which Trustpilot judged 17 baseless and removed 5 only because the reviewer stopped answering [REV-TPX]. EZCare, the same practice on the same platform without the subscription, posts a better raw distribution (4.32 vs 4.19) and a score 0.9 worse (3.4 vs 4.3). Meanwhile the site publishes 4.85 under a Trustpilot wordmark while three independent surfaces read 3.86 to 4.3, and the site's own JSON-LD says 4.4 over a review count that is 61 short of reality [WEB]. Under FTC's consumer-review rule and Section 5, a rating displayed with a third party's wordmark that the third party does not report is exactly the artefact an enforcement action starts from, and this category has already been made an example of [PRIOR]. The cheapest risk removal in the entire product surface is to display Trustpilot's number under Trustpilot's logo, label the internal 4.85 as an internal survey, and refresh the JSON-LD. It costs a day and removes a deception exposure. Stopping the flagging of one-star reviews costs nothing and removes the "they tried to delete my review" edits that now sit permanently on the brand SERP.

5. Two numbers to walk in with, and one to refuse to guess. Say "about 45 BBB complaints in the last twelve months, not the 58 on the profile, because roughly a quarter of the recent flow is a different company with a similar name" — and show the arithmetic. Say "our one-star rate has fallen from about 20% to about 14%, and about a point of that is reviews we got taken down." And when asked why review volume halved, say "I can see it fell 59% between last autumn and this summer; I can't tell from outside whether that's fewer patients or a change in how we ask, and that's the first thing I'd want to look at." Being the person in the room who separates the three is worth more than being the person with a fourth revenue estimate.